MedPath

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

Not Applicable
Completed
Conditions
Elevated Blood Pressure
Hypertension
Interventions
Other: Control flexibility
Other: Boxing Training
Registration Number
NCT06413251
Lead Sponsor
University of Texas, El Paso
Brief Summary

The goal of this clinical trial is to determine whether boxing training reduces cardiovascular risk in elevated blood pressure or hypertension stage 1 individuals.

The main questions it aims to answer are (1) if boxing training reduces peripheral and central blood pressure and (2) if boxing training improves cardiovascular function in elevated blood pressure or hypertension stage 1 individuals.

Participants with elevated blood pressure or hypertension stage 1 will be randomly divided into a control group or an intervention group. The latter group will be involved in boxing training, 3 days per week for 6 weeks.

Researchers will compare clinical and cardiovascular outcomes between the control and the intervention group.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • ≥18 years old.
  • Systolic blood pressure between 120-139 mmHg and/or diastolic blood pressure between 80-89 mmHg obtained from 2 different days.
  • an estimated 10-year risk of CVD ≤10%, calculated by the ACC/AHA Pooled Cohort Equations.
  • no current participation in 3 or more days per week of endurance or resistance exercise training.
Exclusion Criteria
  • non-controlled cardiac, pulmonary, or metabolic diseases.
  • smoking, consumption of nutritional supplements containing antioxidants.
  • any physical impairment to exercise.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlControl flexibilityThe control group will perform three days per week 10 minutes a flexibility intervention.
BoxingBoxing TrainingThe boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks
Primary Outcome Measures
NameTimeMethod
Change from baseline brachial blood pressure after week sixpre-intervention and immediately after the intervention

Resting systolic and diastolic blood pressure (mmHg)

Secondary Outcome Measures
NameTimeMethod
Central Blood Pressurepre-intervention and immediately after the intervention

Pulse wave analysis (mmHg)

Vascular functionpre-intervention and immediately after the intervention

Flow mediated dilation (%)

Plethysmographypre-intervention and immediately after the intervention

Forearm and Calf Blood Flow (ml/min/100 ml tissue)

Maximum Oxygen Uptakepre-intervention and immediately after the intervention

Cardiopulmonary Test (ml/kg/min)

Nitric Oxide Bioavailabilitypre-intervention and immediately after the intervention

Blood Biomarker NOx (μmol/L)

Body Fat Percentagepre-intervention and immediately after the intervention

Dual energy x-ray absorptiometry Scan to assess Body Fat %

Lean Masspre-intervention and immediately after the intervention

Dual energy x-ray absorptiometry Scan to assess lean mass (kg)

Quality of Life measured by the short-form 36 (SF-36)pre-intervention and immediately after the intervention

The short form 36 (SF-36) is a short survey that covers a total of 8 sub-dimensions related to physical and mental health: (1) Physical Functioning, (2) Role Limitations due to Physical Problems, (3) Social Functioning, (4) Bodily Pain, (5) General Mental Health, (6) Role Limitations due to Mental Problems, (7) Vitality, and (8) General Health Perceptions. The SF-36 includes a diverse mixture of continuous item scaling methods and is comprised of 10 items with balanced multi-item response formats (range from 1 to 5), 7 items with a dichotomous response format (1 or 2), and 19 items with non-balanced multi-item response formats (nine items range from 1 to 3 and ten items range from 1 to 6). To obtain the raw score for each sub-dimension, 10 items are reversed. Then, raw values for each sub-dimension are summed. Finally, the raw scores are transformed to a 0-to-100 scale for each sub-dimension. Higher scores indicate higher Quality of Life from 0 (worst) to 100 (best).

Arterial Stiffnesspre-intervention and immediately after the intervention

Pulse wave velocity from carotid to femoral artery (m/s)

C Reactive Protein (CRP) to assess inflammationpre-intervention and immediately after the intervention

Blood Biomarker CRP (mg/L)

Interleukin-6 (IL-6) to assess inflammationpre-intervention and immediately after the intervention

Blood Biomarker IL-6 (pg/ml)

Tumor necrosis factor alfa (TNFα) to assess inflammationpre-intervention and immediately after the intervention

Blood Biomarker TNFα (pg/ml)

Superoxide dismutase (SOD) to assess oxidative stresspre-intervention and immediately after the intervention

Blood Biomarker SOD (mU/ml)

8-isoprostane to assess inflammationpre-intervention and immediately after the intervention

Blood Biomarker 8-isoprostane (pg/ml)

Total Antioxidant Capacity (TAC) to assess oxidative stresspre-intervention and immediately after the intervention

Blood Biomarker TAC (mM/ml)

Lipid Profilepre-intervention and immediately after the intervention

Blood Biomarkers HDL-C, LDL-C, and total cholesterol (mg/dl)

Weightpre-intervention and immediately after the intervention

Weight in kilograms

Heightpre-intervention and immediately after the intervention

Height in meters

Trial Locations

Locations (1)

The University of Texas at El Paso

🇺🇸

El Paso, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath